Our partnerships

Through our many partnerships we continuously seek to improve human health across the globe by working together in pursuing new knowledge and identifying opportunities to translate research into tangible outcomes. Translational research is of key importance to us. This snapshot of our current projects highlights how we work across disciplines, including lab-based medical science, applied clinical research, and social and public health research.


Pfizer and MNHS – a strategic alliance

The Faculty of Medicine, Nursing and Health Sciences at Monash was the first non-USA-based entity to join Pfizer’s Centers for Therapeutic Innovation (CTI), a unique model for academic-industry collaboration, designed to bridge the gap between early scientific discovery and its translation into new medicines.

The strategic alliance between Pfizer and MNHS has been established to co-develop high value targets, currently focusing on novel therapies for cancer and fibrosis. Pfizer has benefited from the partnership by getting access to world-leading science and novel therapeutic targets while Monash has gained exposure to the industry translation process and seized opportunities to engage at a very early stage of the R&D process.

Read more about Pfizer’s Centers for Therapeutic Innovation (CTI) here


Hazelwood Mine Fire Health Study

In response to community concerns about the long-term health effects of the 2014 Morwell open-cut mine fire, the Victorian government commissioned the Hazelwood Mine Fire Health Study. Led by the Monash School of Public Health and Preventative Medicine and the University's School of Rural Health, a group of four universities together with CSIRO was awarded the $27 million study tender on the basis of extensive demonstrated experience and a strong existing network of collaborators within the University and public health sectors.

Read more about the project here


Merck Sharp & Dohme (MSD) license deal

A suite of drugs developed by the Cancer Therapeutics Cooperative Research Centre (CTx) based on discoveries initially made by Professor Stephen Jane, Head of the Monash Central Clinical School, has recently been licensed to global healthcare leader Merck Sharp & Dohme (MSD) in what is believed to be one of the largest preclinical licensing deals involving an Australian discovery. Under the terms of the license deal, worth up to $730 million, MSD will be responsible for research and development, including clinical development and worldwide commercialisation of products based on PRMT5 protein inhibitors.  Prof. Jane, who first discovered the importance of PRMT5 in his search for inhibitory dugs, stressed that the early process from initial discovery to commercialisation was ‘extremely difficult’ and cobbled together with support from a  variety of sources. Jane: “Only due to the partnership with CTx did the commercialisation pathway become clearer, emphasizing the need for similar pathways for new discoveries in the future.”

Read more about the licensing deal here


ASPREE – International Study Consortium

ASPREE (ASPirin in Reducing Events in the Elderly) is a USD$50 million international collaborative project led by Monash University and funded by the USA and Australian governments, drawing together scientific research strengths from several Universities, Australian general practitioners (GPs) and healthy older people. ASPREE will determine whether daily low-dose aspirin prevents or delays the onset of age-related illness such as cardiovascular disease (heart attack and stroke), dementia and depression and if the benefits outweigh the risks, such as bleeding. Professor John McNeil (Head of School of Public Health and preventive Medicine, Monash) co-chairs the ASPREE International Steering Committee and as Co-principal Investigator on the study was instrumental in the development and establishment of this internationally important clinical program. The Study was funded on the basis of the extensive track records of Public Health research achievements, clinical expertise, database and registry management experience inherent in the team.

Read more about ASPREE here


Grey Innovation and MNHS collaborate to develop breakthrough technology

A collaboration between the Monash institute of Cognitive and Clinical Neurosciences, the Australian Technology Commercialisation firm ‘Grey Innovation’ and DreamWorks contractor Torus Games has resulted in the development of a breakthrough product for the treatment of cognitive delay in pre-school aged children. The TALI Attention Training Program, is a world first tablet technology, designed to assist children with developmental disabilities, such as Autism Spectrum Disorders and Down Syndrome, stay focused, and is aimed at facilitating learning and inclusion within the school environment. The technology, which was chosen as a finalist in the annual The Australian Innovation Challenge awards, has been funded by an ARC Linkage grant to Monash University, Grey Innovation and Torus Games.

Read more about TALI here